The investigators adopted the CAMS（Chinese Academy of Medical Sciences）-2009 trial for pediatric acute myeloid leukemia (AML) patients between 2009 to 2015, in which a risk-stratified strategy and dose-dense intensive chemotherapy were introduced. The outcomes of CAMS-2009 trial were retrospectively analyzed, and compared to the CAMS-2005 trial.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
overall survival (OS)
Timeframe: From date of diagnosed until the date of death from any cause, assessed up to 60 months
event-free survival (EFS)
Timeframe: From date of diagnosed until the date of first relapse or date of death from any cause, whichever came first, assessed up to 60 months
complete remission (CR)
Timeframe: through study completion, an average of 1 year